Claims Scope:

Issue fee paid.  Patent will issue on February 27, 2024 as Patent No. 11,911,458. 

Sequence-specific Method Claims 

– method of treating cells (claim 1)  

– treating HIV infection in a subject (claims 21, 30)  

1. all of SEQ ID NO: 97 (CCR5 guide seq), SEQ ID NO: 6 (Vif guide seq), and SEQ ID NO: 7 (Tat guide seq)  

1. at 90% sequence identity to sequences  

1. Note claims 21 and 30 require infusing the transduced HIV-specific CD4+ T-cells into the subject.